Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M, Tanzawa F, Iwasaki S, Inaba F, Fujiwara K, Iwadare H, Echigo T, Nakamura Y, Shibata T, Suzuki K, Yasumatsu I, Nakayama A, Sasazawa Y, Tashiro E, Imoto M, Kurakata S.
Kiga M, et al. Among authors: shibata t.
Anticancer Drugs. 2012 Jan;23(1):119-30. doi: 10.1097/CAD.0b013e32834c6a33.
Anticancer Drugs. 2012.
PMID: 22008853